1. Home
  2. SLN vs WEYS Comparison

SLN vs WEYS Comparison

Compare SLN & WEYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$10.38

Market Cap

300.9M

Sector

Health Care

ML Signal

HOLD

Logo Weyco Group Inc.

WEYS

Weyco Group Inc.

HOLD

Current Price

$39.86

Market Cap

331.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
WEYS
Founded
1994
1906
Country
United Kingdom
United States
Employees
88
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
300.9M
331.9M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
SLN
WEYS
Price
$10.38
$39.86
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$42.60
N/A
AVG Volume (30 Days)
559.5K
17.3K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
3.24%
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
N/A
$276,169,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$61.70
Revenue Growth
N/A
N/A
52 Week Low
$4.19
$27.25
52 Week High
$11.06
$39.98

Technical Indicators

Market Signals
Indicator
SLN
WEYS
Relative Strength Index (RSI) 71.89 67.00
Support Level $5.87 $30.78
Resistance Level N/A N/A
Average True Range (ATR) 0.80 1.29
MACD 0.37 0.22
Stochastic Oscillator 85.24 91.92

Price Performance

Historical Comparison
SLN
WEYS

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About WEYS Weyco Group Inc.

Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, South Africa, and Australia.

Share on Social Networks: